Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,091 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Health-related quality of life on combination therapy with peritoneal dialysis and hemodialysis in comparison with hemodialysis and peritoneal dialysis: A cross-sectional study.
Tanaka M, Ishibashi Y, Hamasaki Y, Kamijo Y, Idei M, Kawahara T, Nishi T, Takeda M, Nonaka H, Nangaku M, Mise N. Tanaka M, et al. Among authors: takeda m. Perit Dial Int. 2020 Sep;40(5):462-469. doi: 10.1177/0896860819894066. Epub 2020 Jan 17. Perit Dial Int. 2020. PMID: 32063200
Importance of EQA/PT for the detection of genetic variants in comprehensive cancer genome testing.
Matsushita K, Ishige T, Watanabe K, Akahane T, Tanimoto A, Yoshimoto M, Yamakuchi M, Hashiguchi T, Okugawa Y, Ikejiri M, Yamaguchi T, Yamasaki T, Takeda M, Hibi M, Akiyama N, Shimizu K, Hashimoto N, Sato H, Tanaka Y, Amari F; EQA working group of Japan Association for Clinical Laboratory Science(JACLS). Matsushita K, et al. Among authors: takeda m. Sci Rep. 2025 Jan 7;15(1):1036. doi: 10.1038/s41598-024-84714-4. Sci Rep. 2025. PMID: 39762492 Free article.
A Phase II, Open Label, Single-Arm Study on the Efficacy of Cabozantinib in Patients With Advanced/Metastatic Nonsmall Cell Lung Cancer Harboring MET Exon 14 Alterations who Developed Acquired Resistance to Tepotinib or Capmatinib (CAPTURE Trial).
Takeda M, Ota M, Iwama E, Sugawara S, Shukuya T, Umemura S, Tanaka H, Oki M, Takahama T, Masuda T, Nogami N, Shimokawa M. Takeda M, et al. Clin Lung Cancer. 2024 Dec 9:S1525-7304(24)00267-5. doi: 10.1016/j.cllc.2024.12.004. Online ahead of print. Clin Lung Cancer. 2024. PMID: 39743377
4,091 results